ID   IMR-32rCARBO1000
AC   CVCL_ZX18
DR   Wikidata; Q102114224
RX   PubMed=31581737;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Paraplatin).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): PubMed=31581737
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9
ST   D16S539: 8
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 30,31
ST   D2S1338: 23,24
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,12
ST   Penta E: 7,15
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0346 ! IMR-32
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 29-06-23; Version: 5
//
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//